当前位置:首页 - 行情中心 - 泽璟制药-U(688266) - 财务分析 - 现金流量表

泽璟制药-U

(688266)

  

流通市值:275.30亿  总市值:275.30亿
流通股本:2.65亿   总股本:2.65亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金942,973,341.74893,841,042.09625,943,869.14384,677,977.23
  收到其他与经营活动有关的现金201,757,747.59161,640,556.03140,197,696.5190,465,216.64
  经营活动现金流入小计1,144,731,089.331,055,481,598.12766,141,565.65475,143,193.87
  购买商品、接受劳务支付的现金11,601,930.2942,077,111.9824,889,535.5413,814,093.57
  支付给职工以及为职工支付的现金117,092,176.67343,267,920.11256,185,507.54176,226,028.9
  支付的各项税费17,789,141.9780,563,439.9851,276,975.1231,750,901.95
  支付其他与经营活动有关的现金160,833,344.28618,355,112.29450,523,469.31270,372,445.53
  经营活动现金流出小计307,316,593.211,084,263,584.36782,875,487.51492,163,469.95
  经营活动产生的现金流量净额837,414,496.12-28,781,986.24-16,733,921.86-17,020,276.08
二、投资活动产生的现金流量:
  收回投资收到的现金396,585,777.77116,123,50065,492,20017,179,200
  取得投资收益收到的现金31,652,958.349,708,791.34451,333.33194,000
  投资活动现金流入小计428,238,736.11125,832,291.3465,943,533.3317,373,200
  购建固定资产、无形资产和其他长期资产支付的现金33,799,619.54181,466,703.44132,497,229.0679,715,800.36
  投资支付的现金999,454,330.32---
  投资活动现金流出小计1,033,253,949.86181,466,703.44132,497,229.0679,715,800.36
  投资活动产生的现金流量净额-605,015,213.75-55,634,412.1-66,553,695.73-62,342,600.36
三、筹资活动产生的现金流量:
  取得借款收到的现金56,000,0001,126,882,468.69616,021,145.08431,521,145.08
  筹资活动现金流入小计56,000,0001,126,882,468.69616,021,145.08431,521,145.08
  偿还债务支付的现金201,900,0001,009,900,000.01507,070,075.83317,070,075.83
  分配股利、利润或偿付利息支付的现金5,794,834.326,094,317.7919,466,662.0812,721,068.85
  支付其他与筹资活动有关的现金6,286,829.4498,389,163.0690,169,404.0975,817,164.91
  筹资活动现金流出小计213,981,663.741,134,383,480.86616,706,142405,608,309.59
  筹资活动产生的现金流量净额-157,981,663.74-7,501,012.17-684,996.9225,912,835.49
四、汇率变动对现金及现金等价物的影响-4,503,785.11-690,409.18-527,602.39-453,654.23
五、现金及现金等价物净增加额69,913,833.52-92,607,819.69-84,500,216.9-53,903,695.18
  加:期初现金及现金等价物余额124,657,673.39217,265,493.08217,265,493.08217,265,493.08
  期末现金及现金等价物余额194,571,506.91124,657,673.39132,765,276.18163,361,797.9
补充资料:
  净利润--165,126,809.51--75,569,945.5
  资产减值准备-3,358,105.87-3,358,109.26
  固定资产和投资性房地产折旧-23,670,592.77-12,070,051.42
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-23,670,592.77-12,070,051.42
  无形资产摊销-18,628,973.79-9,399,847.16
  长期待摊费用摊销-5,628,883.62-2,869,292.11
  处置固定资产、无形资产和其他长期资产的损失--810.44--810.44
  公允价值变动损失--841,343.86--
  财务费用--29,626,727.88--13,409,228.02
  投资损失--358,908.26--800,771.56
  递延所得税--3,996,929.58--2,009,690.11
    递延所得税负债增加--3,996,929.58--2,009,690.11
  存货的减少-9,594,088.46--15,287,856.49
  经营性应收项目的减少--24,395,644.32--39,844,818.4
  经营性应付项目的增加-123,550,059.88-85,177,377.53
  其他-3,339,332.01-10,828,754.36
  不涉及现金收支的投资和筹资活动金额其他项目-0--
  现金的期末余额-124,657,673.39-163,361,797.9
  减:现金的期初余额-217,265,493.08-217,265,493.08
  现金及现金等价物的净增加额--92,607,819.69--53,903,695.18
公告日期2026-04-292026-03-282025-10-312025-08-23
审计意见(境内)标准无保留意见
TOP↑